There is a newer version of the record available.

Published August 14, 2018 | Version v1
Dataset Open

Analysis of NSD3 Isoform Expression from TCGA-LUSC Data

Description

SGC Open Notebook Project to Characterize the HMTase NSD3

Exp028 Objective: There are two major NSD3 isoforms expressed, long (aa 1-1437) and short (aa 1-645, differing in sequence from 620-645). Importantly, the short isoform was shown to be required for the maintenance of acute myeloid leukemia (AML) [1]. This isoform lacks a SET domain and thus methyltransferase activity. It is not clear if the two isoforms are co-expressed or independently regulated. As a first attempt to study differential regulation of the two isoforms, I have used the TCGA-LUSC dataset to analyze relative expression levels in the context of squamous cell lung cancer (LUSC) [2]. 

References: 

1. Shen C, Ipsaro JJ, Shi J, et al. NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Molecular cell. 2015;60(6):847-859. doi:10.1016/j.molcel.2015.10.033.  
2. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nature genetics. 2013;45(10):1113-1120. doi:10.1038/ng.2764.

Notes

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Files

NSD3_splicing_exp28.pdf

Files (758.3 kB)

Name Size Download all
md5:1db97924950123ecfa14d756792fcf12
749.7 kB Preview Download
md5:c1631ec6cef4d81e16bc047f4eee9857
8.6 kB Download